Healthcare Services Group, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. The company provides housekeeping, laundry, linen, facility maintenance and dietary services, primarily to U.S. healthcare facilities.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $423.4 million | $417.2 million | +1.5% |
| Costs of services provided | $358.9 million | $362.4 million | -1.0% |
| Selling, general and administrative expense | $46.9 million | $40.0 million | +17.1% |
| Income before income taxes | $21.3 million | $16.2 million | +31.9% |
| Net income | $15.3 million | $11.7 million | +31.2% |
| Diluted earnings per share | $0.21 | $0.16 | Up $0.05 |
| Operating cash flow | -$26.0 million | -$16.3 million | Outflow increased |
Costs of services were 84.8% of revenue, versus 86.9%; SG&A was 11.1%, versus 9.6%. Net income was 3.5% of revenue, versus 2.7%. Reported investment and other income was $5.7 million, up from $3.1 million, while interest expense rose to $2.0 million from $1.8 million. The investment-income increase was driven primarily by market movements in deferred-compensation plan investments.
Segments: Housekeeping revenue declined 1.5% to $190.6 million, reflecting fewer facilities served year over year. Dietary revenue increased 4.1% to $232.9 million, supported by contract modifications that passed labor and supply cost increases to customers. Segment income before taxes was $18.4 million for Housekeeping, down 8.0%, and $17.6 million for Dietary, up 20.2%.
Liquidity, debt and cash flow
- At March 31, cash and cash equivalents were $29.3 million; restricted cash equivalents were $24.7 million; and marketable securities were $75.6 million. The company reported working capital of $371.0 million and a current ratio of 2.8 to 1.
- Borrowings under the $300 million revolving line were $40.0 million, up from $25.0 million at year-end. Outstanding letters of credit of $72.4 million reduced stated remaining availability to $187.6 million. The company reported compliance with both credit covenants.
- Operating cash outflow was primarily attributed to higher accounts receivable and lower accrued payroll. Management cited delayed government reimbursements to customers following a cybersecurity incident at Change Healthcare.
- Investing activities provided $11.7 million, including $16.6 million of proceeds from marketable-security sales; the company also invested $2.8 million for a 25% interest in a healthcare consulting company. Financing activities provided $14.0 million, including $15.0 million in short-term borrowings.
- Net accounts and notes receivable were $430.4 million, up from $408.3 million at December 31, 2023. The allowance for doubtful accounts was $95.6 million, compared with $91.7 million at year-end.
Changes, outlook and risks
- Management estimated 2024 capital expenditures of approximately $5 million to $7 million; $2.2 million had been spent through March 31. No specific material capital-expenditure commitments through year-end were reported.
- The company did not provide a numerical revenue or earnings forecast. Management said existing cash, operating cash flows and credit capacity should meet foreseeable operating and growth needs, while noting there is no assurance.
- Management cited persistent inflation, labor shortages and wage growth, and nursing-home occupancy and workforce participation below recovery targets. Higher labor, supply and equipment costs may pressure results if not passed through to customers.
- Genesis Healthcare accounted for $38.8 million, or 9.2%, of Q1 2024 revenue, down from $48.1 million, or 11.5%, in Q1 2023. Genesis-related delinquent notes receivable are included in the company’s credit-loss disclosures; a significant reduction in business or payment delays could adversely affect results and cash flow.
- The company has a pending Employee Retention Credit claim but recognized no benefit, stating receipt was not reasonably assured as of the filing. It reported no material subsequent events through the filing date.
- Management reported that internal control over financial reporting was not effective because of a material weakness in controls over accrued payroll, specifically accrued vacation. Prior-period accrued-vacation errors were assessed as immaterial and corrected; remediation is underway, with no guarantee it will be sufficient.
- Various legal claims and tax matters are ongoing. The company said it cannot reasonably estimate possible losses for certain pending litigation; it did not expect tax matters to materially affect financial position or results based on its current assessment.
Important facts for investors to verify
- Whether the accrued-vacation control weakness is remediated and whether enhanced controls prevent future misstatements.
- Whether the Change Healthcare disruption and customer reimbursement delays resolve, and how receivables, collections and operating cash flow evolve.
- Genesis’s payment performance, delinquent notes and ongoing contribution to revenue.
- Whether labor and supply cost increases can be passed through, particularly given the different segment cost trends.
- Credit-facility availability after letters of credit, covenant compliance and the effect of floating interest rates on borrowing costs.
- Any developments on the ERC claim, pending litigation or other contingencies that could affect reported results.